The design of targeted kinase inhibitors frequently combines heteroaromatic rings with specialized functional groups that help define the molecular architecture. In Brigatinib, the dimethylphosphine oxide group is a distinctive structural feature.
(2-((2,5-Dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (CAS 1197953-49-3) is an advanced pharmaceutical intermediate that already contains both the substituted pyrimidine ring and the dimethylphosphine oxide-bearing aromatic fragment.
Its role is to provide a substantial portion of the molecular framework required for Brigatinib assembly.
Product Identity and Specifications
This compound consists of a dichloropyrimidine ring linked to an aromatic amino group, with a dimethylphosphine oxide substituent on the phenyl ring.
- · Product Name: (2-((2,5-Dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
- · CAS Number: 1197953-49-3
- · Molecular Formula: C₁₂H₁₂Cl₂N₃OP
- · Molecular Weight: 316.12 g/mol
- · Synonyms: 2,5-Dichloro-N-(2-(dimethylphosphoryl)phenyl)pyrimidin-4-amine; Brigatinib phosphine oxide intermediate; AP26113 intermediate 1
- · Typical Purity: 98% as listed in the supplied product specification
- · Physical Form: Solid
Chemical reference and commercial supplier records confirm the formula and molecular weight.
Understanding the Dimethylphosphine Oxide Group
The dimethylphosphine oxide group is a defining structural element of this intermediate.
Unlike a conventional phosphonate ester, this molecule contains a carbon-phosphorus bond within a phosphine oxide structure.
This distinction matters when describing its chemistry. The compound should be identified as a dimethylphosphine oxide derivative, rather than incorrectly classified as a phosphonate intermediate.
The group is already incorporated into the aromatic fragment before the compound enters later stages of Brigatinib synthesis.
The Role of the Dichloropyrimidine Framework
The pyrimidine ring contains two chlorine substituents at different positions. These substituents provide distinct functional handles for subsequent transformations.
The 4-position is already connected to the phenylamino group, while the remaining chlorine substituents enable further substitution according to the selected synthetic route.
Patent literature identifies CAS 1197953-49-3 as a Brigatinib intermediate and describes its preparation through reaction of a dichloropyrimidine precursor with a dimethylphosphine oxide-substituted aniline.
This demonstrates the importance of controlling substitution position and reaction selectivity during preparation.
How It Connects to Brigatinib
Brigatinib is an oral ALK and ROS1 tyrosine kinase inhibitor used in the treatment of ALK-positive non-small cell lung cancer.
Its structure contains two major components:
- · A pyrimidine-containing fragment bearing the dimethylphosphine oxide-substituted phenyl group.
- · A methoxy-substituted aniline fragment carrying a piperidine-methylpiperazine side chain.
CAS 1197953-49-3 supplies the first of these structural components. The second is represented by the Brigatinib aniline intermediate CAS 761440-75-9.
The final assembly involves further substitution and coupling chemistry. The exact sequence and process conditions depend on the selected manufacturing route.
This two-fragment perspective helps explain why both compounds are important products for customers working on Brigatinib-related pharmaceutical synthesis.
What Determines Intermediate Quality?
Because the compound contains a reactive dichloropyrimidine framework, quality assessment should include both chemical purity and functional-group integrity.
Chemical identity: Confirm CAS 1197953-49-3 and the correct molecular structure.
Assay: Evaluate chromatographic purity using a suitable analytical method.
Halogenated impurities: Monitor incompletely substituted or structurally related pyrimidine compounds.
Phosphine oxide integrity: Confirm that the dimethylphosphine oxide structure remains intact.
Residual solvents: Assess solvent residues according to the intended downstream application.
Storage: Follow supplier-specific recommendations. Commercial reference records commonly recommend sealed storage under an inert atmosphere at 2–8°C.
SHLZ Pharma: Process Development and Production Support
Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. provides pharmaceutical intermediate and API development, customization, and production services.
Its official profile describes a 1,000-square-meter R&D laboratory, two pilot production workshops, and a factory equipped for different reaction and separation processes. The company reports laboratory customization from grams to kilograms and pilot/factory production from hundreds of kilograms to tons.
For advanced intermediates containing multiple functional groups, this development infrastructure can be relevant when evaluating process optimization, impurity control, and production scale-up.
Conclusion
(2-((2,5-Dichloropyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide (CAS 1197953-49-3) is an advanced Brigatinib intermediate with a molecular formula of C₁₂H₁₂Cl₂N₃OP and molecular weight of 316.12 g/mol.
Its key structural features are the dichloropyrimidine ring, phenylamino linkage, and dimethylphosphine oxide group. Together, these form a major portion of the Brigatinib molecular framework.
For procurement, buyers should evaluate identity, assay, halogenated impurity profile, phosphine oxide integrity, storage requirements, and batch consistency.
Post time: Nov-13-2026
